TITLE:
Target Prediction and Molecular Mechanism of Compound Honggencao for Upper Respiratory Tract Infection Based on Network Pharmacology
AUTHORS:
Junhui Hu, Jingyi Zhao, Ying Wang, Yinhui Yao, Song Jiang, Jianhui Li, Xun Xiao, Yanping Jiang, Yanwu Zhao
KEYWORDS:
Network Pharmacology, Compound Honggencao, Upper Respiratory Tract Infection, Target, Molecular Mechanism
JOURNAL NAME:
Chinese Medicine,
Vol.11 No.1,
March
31,
2020
ABSTRACT: Objective: The target prediction and molecular mechanism of compound Honggencao in
the treatment of upper respiratory tract infection were investigated based on network pharmacology. Methods: In the database of Traditional Chinese Medicine Systems Pharmacology Database
and Analysis Platform, chemical composition and potential targets of compound
Honggencao were mined, and the target gene of upper respiratory tract infection
of compound Honggencao was extracted from GeneCards databases. The protein-protein interaction of
target genes was constructed. Then, the essential genes of enrichment of KEGG
pathway analysis and functional analysis were analysed. Results: Compound Honggencao had 69 kinds of active ingredients. The upper respiratory
tract infection of the target gene was 186 that built compound Honggencao on the relationship between upper
respiratory tract infections of protein interaction networks, which had a total
of 186 nodes, 3515 sides. Fifty-six essential genes were including IL-17, EGFR
and CDND1, and so on. Gene ontology analysis had 2567 items, and pathway
analysis was 166 items. The main signaling pathways involved with IL-17 signaling
pathways, tumour necrosis factor signal pathway and human cytomegalovirus
infection, and so on. Conclusion: The pharmacological action of compound
Honggencao on upper respiratory tract infection was characterized by the
synergistic effect of multiple components and multiple targets, which provided
an absolute theoretical basis for the research on the pharmacological direction
of molecular signaling pathway and a specific theoretical basis for clinical
use.